In the past week, TARS stock has gone up by 13.82%, with a monthly decline of -11.89% and a quarterly plunge of -19.87%. The volatility ratio for the week is 6.86%, and the volatility levels for the last 30 days are 6.21% for Tarsus Pharmaceuticals Inc The simple moving average for the last 20 days is -2.09% for TARS stock, with a simple moving average of 10.53% for the last 200 days.
Is It Worth Investing in Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Right Now?
TARS has 36-month beta value of 1.06. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TARS is 31.03M, and currently, short sellers hold a 25.66% ratio of that float. The average trading volume of TARS on July 04, 2024 was 634.69K shares.
TARS) stock’s latest price update
The stock of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has increased by 4.36 when compared to last closing price of 27.55. Despite this, the company has experienced a 13.82% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-05-29 that IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences:
Analysts’ Opinion of TARS
Many brokerage firms have already submitted their reports for TARS stocks, with Goldman repeating the rating for TARS by listing it as a “Neutral.” The predicted price for TARS in the upcoming period, according to Goldman is $19 based on the research report published on November 20, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see TARS reach a price target of $44. The rating they have provided for TARS stocks is “Outperform” according to the report published on July 18th, 2023.
TARS Trading at -12.66% from the 50-Day Moving Average
After a stumble in the market that brought TARS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.35% of loss for the given period.
Volatility was left at 6.21%, however, over the last 30 days, the volatility rate increased by 6.86%, as shares sank -12.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.41% lower at present.
During the last 5 trading sessions, TARS rose by +14.53%, which changed the moving average for the period of 200-days by +79.24% in comparison to the 20-day moving average, which settled at $29.16. In addition, Tarsus Pharmaceuticals Inc saw 41.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARS starting from Farrow Jeffrey S, who sale 10,445 shares at the price of $27.47 back on Jun 18 ’24. After this action, Farrow Jeffrey S now owns 18,136 shares of Tarsus Pharmaceuticals Inc, valued at $286,924 using the latest closing price.
Azamian Bobak R., the President/CEO and Board Chair of Tarsus Pharmaceuticals Inc, sale 10,415 shares at $30.60 during a trade that took place back on Mar 18 ’24, which means that Azamian Bobak R. is holding 26,456 shares at $318,699 based on the most recent closing price.
Stock Fundamentals for TARS
Current profitability levels for the company are sitting at:
- -2.7 for the present operating margin
- 0.94 for the gross margin
The net margin for Tarsus Pharmaceuticals Inc stands at -2.56. The total capital return value is set at -0.51. Equity return is now at value -66.07, with -52.88 for asset returns.
Based on Tarsus Pharmaceuticals Inc (TARS), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -4.37. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 4213.24.
Currently, EBITDA for the company is -142.28 million with net debt to EBITDA at 1.07. When we switch over and look at the enterprise to sales, we see a ratio of 16.08. The receivables turnover for the company is 1.84for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.01.
Conclusion
To put it simply, Tarsus Pharmaceuticals Inc (TARS) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
